OPKO Health, Inc. Earnings Recaps
Q2 2026
Jul 30, 2026
OPKO Health's shares surged 35.2% following Q2 2026 results, driven primarily by clear progress across multiple clinical pipeline programs and sustained financial strength, which appear to have exceeded investor expectations.
Key takeaways
- ModeX advanced five clinical trial programs spanning oncology, immunology, and vaccines, with an anticipated sixth in vivo CAR-T asset to enter clinical trials by end of 2026 or early 2027.
- Merck-funded MDX2201 vaccine against Epstein-Barr virus is completing Phase I data analysis, with Phase II study design expected by year-end.
- Early clinical milestones for MDX2001, MDX2003, MDX2004, and MDX2301 highlight diversified pipeline activity, including ongoing Phase I trials and planned data presentations in late 2026 and 2027.
- Solid balance sheet and operating efficiency improvements sustained a strong cash position while enabling continued R&D funding and capital return via stock repurchases.
- Collaborations with Regeneron and BARDA bolster pipeline breadth, supporting late-stage immuno-oncology and infectious disease programs underpinned by multi-specific antibody platform technology.
Q3 2025
Oct 30, 2025
OPKO Health's Q3 2025 results showcased strategic progress, highlighted by the successful sale of its oncology division and a focus on core clinical operations, driving a commitment to shareholder value.
Key takeaways
- Completed the sale of BioReference Health's oncology division for $192.5 million plus an additional $32.5 million in performance-based earn-out.
- Achieved a 5.3% increase in testing volume at BioReference, with a 20% rise in adoption of the 4Kscore test for prostate cancer.
- Repurchased $25.1 million in stock during 2025 to enhance shareholder returns, with $126 million remaining under the repurchase program.
- Advanced pipeline with four therapeutics in clinical development, including promising candidates in the immuno-oncology space and a COVID-19 antibody initiative.
- Focused on operational efficiencies and growth through new customer segments and revenue streams, maintaining a streamlined workforce at BioReference.